Newsroom | 92451 results

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as of December 18, 2025: Total number of shares outstanding:       92,197,823 ordinary shares...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ (mosunetuzumab-axgb), as a subcutaneous (SC) formulation, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy, based on results from the Phase I/II GO29781 study. Based on the study re...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the French medicines safety agency ANSM (Agence nationale de sécurité du médicament et des produits de santé) has granted compassionate use authorization (Autorisation d’Accès Compassionnel, or AA...

WASHINGTON--(BUSINESS WIRE)--CMMI has disrupted patient access, undermined providers, operated with little accountability, and wasted billions of taxpayer dollars....

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market (“Nasdaq”) from the NYSE American LLC (“NYSE American”). The Company expects that its common shares will cease trading on the NYSE American at market close...

NORTH BETHESDA, Md.--(BUSINESS WIRE)--FDA has qualified the first surrogate endpoint for bone fractures in anti-osteoporosis drug trials for at-risk post-menopausal women....

DUBLIN--(BUSINESS WIRE)--The "ENT Disorder Treatment Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The ENT disorder treatment market is experiencing rapid transformation as organizations adopt new medical technologies and evolving care models to address complex clinical and operational challenges. Senior decision-makers are seeking strategies that enable both enhanced patient outcomes and sustainable organizational performance in this dynamic he...

DUBLIN--(BUSINESS WIRE)--The "Thyroid Eye Disease Treatments Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The thyroid eye disease treatments market is undergoing substantial transformation, fueled by new therapies, advanced diagnostics, and evolving care pathways. As a complex autoimmune disorder, thyroid eye disease challenges health systems and presents significant opportunities for innovation and patient-centered solutions. Market Snapshot:...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans...

DUBLIN--(BUSINESS WIRE)--The "Narcolepsy Treatment Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. Senior leaders in the narcolepsy treatment market face an industry defined by technological advancement, shifting care expectations, and complex policy demands. Navigating this environment requires informed decision-making and operational agility to respond to rapid sector evolution. Narcolepsy Treatment Market Snapshot The global narcolepsy treatmen...